newsfilter
← Latest News
PR Newswire·

Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates

Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it will halt the registration-intended PRECISION1 trial of nab-sirolimus in patients with solid...